Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | DDX3X | O00571 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957229 | 0.86 | KMT2A (0.54) | SMN1; SMN2MEN1KMT2APOLBHTT | |
| SCHEMBL7143990 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1KMT2APOLBHTT | |
| SCHEMBL13836493 | 0.80 | ALDH1A1 (0.61) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL2968585 | 0.80 | ALDH1A1 (0.55) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL28775114 | 0.80 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1KMT2APOLBHTT | |
| SCHEMBL2963623 | 0.77 | MAPT (0.54) | SMN1; SMN2HSD17B10MEN1KMT2APOLB | |
| SCHEMBL2960410 | 0.77 | PDE7A (0.54) | SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL1248559 | 0.75 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1KMT2APOLBHTT | |
| SCHEMBL9352334 | 0.75 | SMN1; SMN2 (0.61) | SMN1; SMN2ALOX5HSD17B10MEN1KMT2A | |
| SCHEMBL13408629 | 0.75 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| CN-101384592-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 3135/4885ALOX5 2999/4885HSD17B10 1572/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 3135/4885ALOX5 2999/4885HSD17B10 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.